The critical role of plasmapheresis in ABO-incompatible renal transplantation

Aaron A Tobian, R. Sue Shirey, Robert A. Montgomery, Paul Michael Ness, Karen Eileen King

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Thousands of patients with chronic renal failure die yearly and are unable to have a kidney transplant due to the severe shortage of donors. Therapeutic plasma exchange (TPE) is performed to remove ABO antibodies and permit ABO-incompatible (ABO-I) kidney transplants, but there is only limited research within this area and a lack of standardized protocols for TPE. This article reviews the literature to provide a historical perspective of TPE for ABO-I kidney transplantation and also provides the Johns Hopkins Hospital protocol with a focus on both titers and TPE. STUDY DESIGN AND METHODS: The TPE treatment plan is based on ABO titers with the goal of a titer of 16 or less at the anti-human globulin (AHG) phase before surgery. Pretransplant therapy consists of every-other-day TPE followed immediately by cytomegalovirus hyperimmune globulin. ABO antibody titers are closely monitored before and after transplantation. After transplantation, TPE therapy is performed for all patients to prevent rebound of anti-A and anti-B titers until tolerance or accommodation occurs. TPE is discontinued and reinstituted based on the clinical criteria of creatinine levels, biopsy results, and ABO titer. RESULTS: Fifty-three ABO-I kidney transplants have been completed with no episodes of hyperacute antibody-mediated rejection (AMR) and only three episodes of AMR. One-year death-censored graft survival is 100 percent and patient survival is 97.6 percent. CONCLUSIONS: While randomized clinical trials are needed to evaluate the optimal method and protocol to remove ABO antibodies, the current literature and our results indicate a critical role for TPE in ABO-I renal transplantation.

Original languageEnglish (US)
Pages (from-to)2453-2460
Number of pages8
JournalTransfusion
Volume48
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

Plasmapheresis
Kidney Transplantation
Plasma Exchange
Therapeutics
Antibodies
Globulins
Transplants
Kidney
Transplantation
Graft Survival
Cytomegalovirus
Chronic Kidney Failure
Creatinine
Randomized Controlled Trials
Tissue Donors

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy

Cite this

The critical role of plasmapheresis in ABO-incompatible renal transplantation. / Tobian, Aaron A; Shirey, R. Sue; Montgomery, Robert A.; Ness, Paul Michael; King, Karen Eileen.

In: Transfusion, Vol. 48, No. 11, 11.2008, p. 2453-2460.

Research output: Contribution to journalArticle

Tobian, Aaron A ; Shirey, R. Sue ; Montgomery, Robert A. ; Ness, Paul Michael ; King, Karen Eileen. / The critical role of plasmapheresis in ABO-incompatible renal transplantation. In: Transfusion. 2008 ; Vol. 48, No. 11. pp. 2453-2460.
@article{9fab65e251284cf390b11700fb49cd31,
title = "The critical role of plasmapheresis in ABO-incompatible renal transplantation",
abstract = "BACKGROUND: Thousands of patients with chronic renal failure die yearly and are unable to have a kidney transplant due to the severe shortage of donors. Therapeutic plasma exchange (TPE) is performed to remove ABO antibodies and permit ABO-incompatible (ABO-I) kidney transplants, but there is only limited research within this area and a lack of standardized protocols for TPE. This article reviews the literature to provide a historical perspective of TPE for ABO-I kidney transplantation and also provides the Johns Hopkins Hospital protocol with a focus on both titers and TPE. STUDY DESIGN AND METHODS: The TPE treatment plan is based on ABO titers with the goal of a titer of 16 or less at the anti-human globulin (AHG) phase before surgery. Pretransplant therapy consists of every-other-day TPE followed immediately by cytomegalovirus hyperimmune globulin. ABO antibody titers are closely monitored before and after transplantation. After transplantation, TPE therapy is performed for all patients to prevent rebound of anti-A and anti-B titers until tolerance or accommodation occurs. TPE is discontinued and reinstituted based on the clinical criteria of creatinine levels, biopsy results, and ABO titer. RESULTS: Fifty-three ABO-I kidney transplants have been completed with no episodes of hyperacute antibody-mediated rejection (AMR) and only three episodes of AMR. One-year death-censored graft survival is 100 percent and patient survival is 97.6 percent. CONCLUSIONS: While randomized clinical trials are needed to evaluate the optimal method and protocol to remove ABO antibodies, the current literature and our results indicate a critical role for TPE in ABO-I renal transplantation.",
author = "Tobian, {Aaron A} and Shirey, {R. Sue} and Montgomery, {Robert A.} and Ness, {Paul Michael} and King, {Karen Eileen}",
year = "2008",
month = "11",
doi = "10.1111/j.1537-2995.2008.01857.x",
language = "English (US)",
volume = "48",
pages = "2453--2460",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The critical role of plasmapheresis in ABO-incompatible renal transplantation

AU - Tobian, Aaron A

AU - Shirey, R. Sue

AU - Montgomery, Robert A.

AU - Ness, Paul Michael

AU - King, Karen Eileen

PY - 2008/11

Y1 - 2008/11

N2 - BACKGROUND: Thousands of patients with chronic renal failure die yearly and are unable to have a kidney transplant due to the severe shortage of donors. Therapeutic plasma exchange (TPE) is performed to remove ABO antibodies and permit ABO-incompatible (ABO-I) kidney transplants, but there is only limited research within this area and a lack of standardized protocols for TPE. This article reviews the literature to provide a historical perspective of TPE for ABO-I kidney transplantation and also provides the Johns Hopkins Hospital protocol with a focus on both titers and TPE. STUDY DESIGN AND METHODS: The TPE treatment plan is based on ABO titers with the goal of a titer of 16 or less at the anti-human globulin (AHG) phase before surgery. Pretransplant therapy consists of every-other-day TPE followed immediately by cytomegalovirus hyperimmune globulin. ABO antibody titers are closely monitored before and after transplantation. After transplantation, TPE therapy is performed for all patients to prevent rebound of anti-A and anti-B titers until tolerance or accommodation occurs. TPE is discontinued and reinstituted based on the clinical criteria of creatinine levels, biopsy results, and ABO titer. RESULTS: Fifty-three ABO-I kidney transplants have been completed with no episodes of hyperacute antibody-mediated rejection (AMR) and only three episodes of AMR. One-year death-censored graft survival is 100 percent and patient survival is 97.6 percent. CONCLUSIONS: While randomized clinical trials are needed to evaluate the optimal method and protocol to remove ABO antibodies, the current literature and our results indicate a critical role for TPE in ABO-I renal transplantation.

AB - BACKGROUND: Thousands of patients with chronic renal failure die yearly and are unable to have a kidney transplant due to the severe shortage of donors. Therapeutic plasma exchange (TPE) is performed to remove ABO antibodies and permit ABO-incompatible (ABO-I) kidney transplants, but there is only limited research within this area and a lack of standardized protocols for TPE. This article reviews the literature to provide a historical perspective of TPE for ABO-I kidney transplantation and also provides the Johns Hopkins Hospital protocol with a focus on both titers and TPE. STUDY DESIGN AND METHODS: The TPE treatment plan is based on ABO titers with the goal of a titer of 16 or less at the anti-human globulin (AHG) phase before surgery. Pretransplant therapy consists of every-other-day TPE followed immediately by cytomegalovirus hyperimmune globulin. ABO antibody titers are closely monitored before and after transplantation. After transplantation, TPE therapy is performed for all patients to prevent rebound of anti-A and anti-B titers until tolerance or accommodation occurs. TPE is discontinued and reinstituted based on the clinical criteria of creatinine levels, biopsy results, and ABO titer. RESULTS: Fifty-three ABO-I kidney transplants have been completed with no episodes of hyperacute antibody-mediated rejection (AMR) and only three episodes of AMR. One-year death-censored graft survival is 100 percent and patient survival is 97.6 percent. CONCLUSIONS: While randomized clinical trials are needed to evaluate the optimal method and protocol to remove ABO antibodies, the current literature and our results indicate a critical role for TPE in ABO-I renal transplantation.

UR - http://www.scopus.com/inward/record.url?scp=55349111829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349111829&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2008.01857.x

DO - 10.1111/j.1537-2995.2008.01857.x

M3 - Article

C2 - 18657072

AN - SCOPUS:55349111829

VL - 48

SP - 2453

EP - 2460

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 11

ER -